Compare · NVS vs RGNT
NVS vs RGNT
Side-by-side comparison of Novartis AG (NVS) and Regentis Biomaterials Ltd. (RGNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. NVS focuses on Biotechnology: Pharmaceutical Preparations, while RGNT focuses on Industrial Specialties.
- NVS is the larger of the two at $305.69B, about 36572.0x RGNT ($8.4M).
- NVS has been more active in the news (5 items in the past 4 weeks vs 2 for RGNT).
- NVS has more recent analyst coverage (25 ratings vs 0 for RGNT).
- Company
- Novartis AG
- Regentis Biomaterials Ltd.
- Price
- -
- -
- Market cap
- $305.69B
- $8.4M
- 1M return
- +6.36%
- -
- 1Y return
- +21.79%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 0
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank
Latest RGNT
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
- Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
- SEC Form EFFECT filed by Regentis Biomaterials Ltd.
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
- SEC Form POS AM filed by Regentis Biomaterials Ltd.
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update